JP2016512564A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016512564A5 JP2016512564A5 JP2016502000A JP2016502000A JP2016512564A5 JP 2016512564 A5 JP2016512564 A5 JP 2016512564A5 JP 2016502000 A JP2016502000 A JP 2016502000A JP 2016502000 A JP2016502000 A JP 2016502000A JP 2016512564 A5 JP2016512564 A5 JP 2016512564A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- probenecid
- improved
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- DBABZHXKTCFAPX-UHFFFAOYSA-N Probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims 6
- 229960003081 probenecid Drugs 0.000 claims 6
- 210000002966 Serum Anatomy 0.000 claims 4
- 206010007554 Cardiac failure Diseases 0.000 claims 3
- 206010019280 Heart failure Diseases 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 230000036470 plasma concentration Effects 0.000 claims 3
- 230000000717 retained Effects 0.000 claims 3
- 108010082834 Brain Natriuretic Peptide Proteins 0.000 claims 2
- 230000001396 anti-anti-diuretic Effects 0.000 claims 2
- 230000001882 diuretic Effects 0.000 claims 2
- 239000002934 diuretic Substances 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000010606 normalization Methods 0.000 claims 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 2
- 229910052708 sodium Inorganic materials 0.000 claims 2
- 239000011734 sodium Substances 0.000 claims 2
- 230000001225 therapeutic Effects 0.000 claims 2
- 230000000747 cardiac effect Effects 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
Claims (11)
- 対象において保持された駆出率を伴う心不全を静脈内注入により治療するための医薬組成物あって、対象における心機能不全を治療するのに有効な血漿中濃度を達成するプロベネシドの量を含む、医薬組成物。
- 前記プロベネシドの量が、向上した標準6分間歩行テストの結果、向上したニューヨーク心臓協会（NYHA）等級、より低い利尿薬の用量要求、より低い血清B型ナトリウム利尿ペプチド（BNP）濃度、血清ナトリウム濃度の正常化、又はこれらの組み合わせをもたらすのに十分な量である、請求項１に記載の医薬組成物。
- ボーラス注入又は持続的静脈内注入のためのものである、請求項１に記載の医薬組成物。
- プロベネシドの用量が約1 mg/kg/日から約100 mg/kg/日までの範囲である、請求項１に記載の医薬組成物。
- 1日当たり約24時間の期間にわたって投与するためのものである、請求項１に記載の医薬組成物。
- 少なくとも１週間の間の治療のためのものである、請求項１に記載の医薬組成物。
- 少なくとも１月の間の治療のためのものである、請求項１に記載の医薬組成物。
- 対象における保持された駆出率を伴う心不全を治療するプロベネシドの治療的血漿中濃度を維持する投与計画で投与するための、プロベネシドを含む、対象における保持された駆出率を伴う心不全を治療するための医薬組成物。
- プロベネシドの治療的血漿中濃度が、向上した標準6分間歩行テストの結果、向上したNYHA等級、より低い利尿薬の用量要求、より低い血清BN）濃度、血清ナトリウム濃度の正常化、又はこれらの組み合わせをもたらすのに十分な量である、請求項８に記載の医薬組成物。
- 前記投与計画が、プロベネシドの用量の静脈内投与を含む、請求項８に記載の医薬組成物。
- 投与が少なくとも１週間の間である、請求項８に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361778826P | 2013-03-13 | 2013-03-13 | |
| US61/778,826 | 2013-03-13 | ||
| PCT/US2014/025930 WO2014160153A1 (en) | 2013-03-13 | 2014-03-13 | Treatment of a diastolic cardiac dysfunction with a trpv2 receptor agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020203311A Division JP2021042248A (ja) | 2013-03-13 | 2020-12-08 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512564A JP2016512564A (ja) | 2016-04-28 |
| JP2016512564A5 true JP2016512564A5 (ja) | 2017-06-01 |
Family
ID=50680137
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016502000A Pending JP2016512564A (ja) | 2013-03-13 | 2014-03-13 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
| JP2020203311A Pending JP2021042248A (ja) | 2013-03-13 | 2020-12-08 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
| JP2023196822A Pending JP2024009140A (ja) | 2013-03-13 | 2023-11-20 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020203311A Pending JP2021042248A (ja) | 2013-03-13 | 2020-12-08 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
| JP2023196822A Pending JP2024009140A (ja) | 2013-03-13 | 2023-11-20 | Ｔｒｐｖ２受容体アゴニストを用いる拡張期心機能不全の治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10583103B2 (ja) |
| EP (1) | EP2968238A1 (ja) |
| JP (3) | JP2016512564A (ja) |
| AU (1) | AU2014244053B2 (ja) |
| CA (1) | CA2904671C (ja) |
| MX (1) | MX2015012547A (ja) |
| WO (1) | WO2014160153A1 (ja) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| EP2882445B1 (en) | 2012-08-13 | 2019-04-24 | Cedars-Sinai Medical Center | Exosomes and micro-ribonucleic acids for tissue regeneration |
| US11357799B2 (en) | 2014-10-03 | 2022-06-14 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| JP7336769B2 (ja) | 2017-04-19 | 2023-09-01 | シーダーズ―シナイ メディカル センター | 骨格筋ジストロフィーを治療する方法及び組成物 |
| BR112020006191A2 (pt) * | 2017-12-12 | 2020-10-06 | Cardiol Therapeutics Inc. | copolímeros em blocos anfifílicos, micelas e métodos para tratamento ou prevenção de insuficiência cardíaca |
| EP3727351A4 (en) | 2017-12-20 | 2021-10-06 | Cedars-Sinai Medical Center | MODIFIED EXTRACELLULAR VESICLES FOR IMPROVED TISSUE DELIVERY |
| WO2021077211A1 (en) * | 2019-10-25 | 2021-04-29 | Cardiol Therapeutics Inc. | Cannabidiol compositions for use in treating heart conditions |
| KR20210150011A (ko) * | 2020-06-03 | 2021-12-10 | 주식회사 삼오파마켐 | 프로베네시드 및 아르기닌의 아미드 유도체, 이를 포함하는 약제학적 조성물 및 이의 제조 방법 |
| CN113861633B (zh) * | 2021-10-14 | 2022-12-20 | 武汉工程大学 | 一种p-n-b阻燃pbs塑料及其制备方法 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3524917A (en) | 1969-02-10 | 1970-08-18 | Merck & Co Inc | Tablets of magnesium probenecid tetrahydrate |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| JPH01211582A (ja) | 1988-02-16 | 1989-08-24 | Tanabe Seiyaku Co Ltd | ベンゾジオキソール誘導体 |
| JP3218038B2 (ja) | 1991-09-09 | 2001-10-15 | ワーナー−ランバート・コンパニー | 尿酸排泄促進剤およびｅａａ拮抗剤の組合せのための医薬組成物 |
| US5444067A (en) | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| US20030212123A1 (en) | 1997-05-05 | 2003-11-13 | Pfizer Inc. | COX-2 selective carprofen for treating pain and inflammation in dogs |
| US6221856B1 (en) | 1999-02-03 | 2001-04-24 | Inologic, Inc. | Inositol derivatives for inhibiting superoxide anion production |
| AU2001268734A1 (en) | 2000-06-28 | 2002-01-08 | Merck & Co., Inc. | Use of agents capable of reducing uric acid levels for the treatment of cardiovascular disease |
| AU2001227030A1 (en) | 2000-11-22 | 2002-06-03 | Lupin Laboratories Limited | Pharmaceutical composition for controlled release of an active ingredient |
| DE10064997A1 (de) | 2000-12-23 | 2002-06-27 | Merck Patent Gmbh | Benzoylpyridazine |
| US20080051428A1 (en) * | 2002-05-15 | 2008-02-28 | Davis Paul J | Pyrroloquinoline quinone drugs and methods of use thereof |
| US7351692B2 (en) | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| WO2004058790A1 (ja) | 2002-12-25 | 2004-07-15 | Kissei Pharmaceutical Co., Ltd. | 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途 |
| EP1666880B1 (en) | 2003-09-11 | 2008-08-20 | Takeda Pharmaceutical Company Limited | Screening method |
| DE10352511A1 (de) | 2003-11-07 | 2005-06-16 | Ernst-Moritz-Arndt-Universität Greifswald | Verwendung von MRP4-Inhibitoren zur Behandlung und/oder Prophylaxe kardiovaskulärer Erkrankungen |
| EP1691891A2 (en) | 2003-11-13 | 2006-08-23 | The Board Of Regents, The University Of Texas System | Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
| US20090017015A1 (en) | 2004-02-20 | 2009-01-15 | Thomas Edward Hughes | Dpp-iv inhibitors for treating neurodegeneration and cognitive disorders |
| JP4902348B2 (ja) | 2004-03-04 | 2012-03-21 | キッセイ薬品工業株式会社 | 含窒素縮合環誘導体、それを含有する医薬組成物およびその医薬用途 |
| JPWO2005095429A1 (ja) | 2004-03-31 | 2008-02-21 | キッセイ薬品工業株式会社 | フェノール誘導体、それを含有する医薬組成物及びその医薬用途 |
| EP2068879A2 (en) | 2006-05-02 | 2009-06-17 | Medical Technology Acceleration Program, Inc. | Pyrroloquinoline quinone drugs and methods of use thereof |
| JP2009149534A (ja) | 2007-12-18 | 2009-07-09 | Japan Health Science Foundation | Ｔｒｐｖ２阻害剤，疾患の予防又は治療剤，薬剤探索用リード化合物，及び薬剤探索方法 |
| KR100951656B1 (ko) | 2008-02-25 | 2010-04-07 | 고려대학교 산학협력단 | 프로베네시드를 포함하는 ｔｒｐｖ２ 활성제 |
| ES2613804T3 (es) | 2008-07-17 | 2017-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Inhibidores de MRP4 y agentes que estimulan la actividad de MRP4 para el tratamiento de trastornos cardíacos |
| US8173690B2 (en) | 2008-09-04 | 2012-05-08 | Ardea Biosciences, Inc. | Compounds, compositions and methods of using same for modulating uric acid levels |
| CA2761156C (en) | 2009-05-07 | 2017-03-14 | University Of Cincinnati | Methods of preventing ischemic injury using peripheral nociceptive stimulation |
| US10806711B2 (en) * | 2011-08-12 | 2020-10-20 | University Of Cincinnati | Method of treating acute decompensated heart failure with probenecid |
-
2014
- 2014-03-13 EP EP14722431.5A patent/EP2968238A1/en active Pending
- 2014-03-13 MX MX2015012547A patent/MX2015012547A/es active IP Right Grant
- 2014-03-13 CA CA2904671A patent/CA2904671C/en active Active
- 2014-03-13 US US14/771,536 patent/US10583103B2/en active Active
- 2014-03-13 WO PCT/US2014/025930 patent/WO2014160153A1/en active Application Filing
- 2014-03-13 AU AU2014244053A patent/AU2014244053B2/en active Active
- 2014-03-13 JP JP2016502000A patent/JP2016512564A/ja active Pending
-
2020
- 2020-12-08 JP JP2020203311A patent/JP2021042248A/ja active Pending
-
2023
- 2023-11-20 JP JP2023196822A patent/JP2024009140A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016512564A5 (ja) | ||
| JP2016530280A5 (ja) | ||
| RU2016109448A (ru) | Комбинированная терапия для лечения глиобластомы | |
| NZ732507A (en) | Improved compositions for treating muscular dystrophy | |
| JP2015518818A5 (ja) | ||
| EA201690738A1 (ru) | Ингалятор сухого порошка | |
| RU2017134443A (ru) | Способ лечения с применением традипитанта | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| RU2018123718A (ru) | Режимы дозирования мелфлуфена для раковых заболеваний | |
| AR104771A1 (es) | Inhalador de polvo seco | |
| WO2014198852A3 (en) | A dosing regime and formulations for type b adenoviruses | |
| JP2018138596A5 (ja) | ||
| JP2016515623A5 (ja) | ||
| JP2018531605A5 (ja) | ||
| MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
| RU2019107146A (ru) | Схемы и способы лечения рассеянного склероза с применением офатумумаба | |
| MX2023007826A (es) | Metodos que comprenden una dosificacion intermitente fija de cediranib. | |
| RU2015139515A (ru) | Комбинированное лечение | |
| JP2017531042A5 (ja) | ||
| JP2017530142A5 (ja) | ||
| RU2014148062A (ru) | Инъекционная фармацевтическая композиция декскетопрофена и трамадола | |
| NZ760033A (en) | Methods to treat opioid use disorder | |
| Harden | Multidrug overdose | |
| EA201590323A1 (ru) | Способ введения активных веществ в головной мозг |